News

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes the sell-off has created an attractive buying opportunity. While ...
One stock in particular has grabbed my attention during this selloff. Regeneron's decline has been epic, and now may be the time to buy. Technical Viewpoint - Seller Exhaustion is Near ...
JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Overweight rating on the shares. The firm ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ ...
Regeneron (REGN) stock remains a buying opportunity, RBC Capital Markets said, ... Arguing that today’s selloff represented a worst-case scenario in the lawsuit, ...
Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price ...
This 120% rise for Regeneron stock since late 2019 can primarily be attributed to 1.the company’s P/S ratio rising 50% to 12.6x revenues vs. 8.4x in 2019, 2. Regeneron’s revenue growth of 44% ...
Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price ...